FFW
CNCR

Fusion Family Wealth’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Fusion Family Wealth’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,438
Closed -$65K – 169
2018
Q4 		$65K Hold
3,438
– – 0.02% 101
2018
Q3 		$85K Hold
3,438
– – 0.02% 93
2018
Q2 		$83K Hold
3,438
– – 0.02% 100
2018
Q1 		$100K Buy
+3,438
New +$97.5K 0.03% 81

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fusion Family Wealth's CNCR Position: Q1 2019 in Review

Fusion Family Wealth sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2019, closing a stake of 3,438 shares — an estimated $65K sold.

Fusion Family Wealth first reported a position in CNCR in Q1 2018 and held it in 4 quarters. The position peaked at $100K in Q1 2018. 21 funds tracked by Wall St. Rank hold CNCR as of Q1 2019.

  • Fusion Family Wealth reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2019 after selling out during the quarter.
  • Fusion Family Wealth sold 3,438 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2019, an estimated $65K.
  • Fusion Family Wealth first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2018 and held it in 4 quarters.
  • Fusion Family Wealth's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $100K in Q1 2018.
  • 21 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2019.

Based on Fusion Family Wealth's 13F filing for Q1 2019, filed 10 May 2019.